Hikma boosts US injectables business with $425 million deal for Custopharm
The acquisition will add 13 approved products and additional pipeline products
Hikma Pharmaceuticals is set to strengthen its US injectables business with a $425 million deal to acquire Custopharm from Water Street Healthcare Partners.
The acquisition will complement Hikma's injectable product portfolio and pipeline by adding 13 approved products and additional pipeline products.
These additional products will bring Hikma's US portfolio close to 130 injectable medicines which, according to Riad Mishlawi, President of Hikma Injectables, represents a more than fivefold increase over the last decade.
The Carlsbad, California-based Custopharm currently markets its products in the US through its commercial arm Leucadia Pharmaceuticals. The company has received 13 US Food and Drug Administration approvals, with four first-to-market Abbreviated New Drug Application (ANDA) approvals — including one with Competitive Generic Therapy (CGT) exclusivity for Calcitonin Salmon, which was launched in May 2021— and one novel 505(b)(2) NDA approval.
Custopharm is a growing business and Hikma says it expects to generate full year 2021 revenue in excess of $80 million.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.